Table 1.
Treatment options for SAC
| Topical antiallergic drops | |||||
|---|---|---|---|---|---|
| SARS‐CoV‐2 infection | Agree | Partially agree | Partially disagree | Disagree | No opinion |
| Not at risk, n (%) | 28 (93%) | 1 (3%) | 0 | 0 | 0 |
| At risk, n (%) | 29 (97%) | 0 | 0 | 0 | 0 |
| Current infection, n (%) | 29 (97%) | 0 | 0 | 0 | 0 |
| Previous infection, n (%) | 28 (93%) | 1 (3%) | 0 | 0 | 0 |
| Low‐dose topical corticosteroids in case of no response | |||||
| Not at risk, n (%) | 14 (47%) | 10 (33%) | 1(3%) | 3 (10%) | 0 |
| At risk, n (%) | 10 (33%) | 6 (20%) | 1 (3%) | 12 (40%) | 0 |
| Current infection, n (%) | 9 (30%) | 4 (13%) | 3 (10%) | 13 (43%) | 0 |
| Previous infection, n (%) | 13 (43%) | 10 (33%) | 1 (3%) | 6 (20%) | 0 |
| Only oral antihistamines | |||||
| Not at risk, n (%) | 10 (3%) | 2 (7%) | 4 (13%) | 11 (37%) | 0 |
| At risk, n (%) | 8 (27%) | 8 (27%) | 3 (10%) | 9 (30%) | 1 (3%) |
| Current infection, n (%) | 6 (20%) | 4 (13%) | 6 (20%) | 11 (37%) | 0 |
| Previous infection, n (%) | 8 (27%) | 1 (3%) | 7 (23%) | 11 (37%) | 0 |